X

Drug Profile

Research programme: cancer therapeutics - Paradigm Pharmaceuticals

Alternative Names: Caspase stimulants research programme - Paradigm Pharmaceuticals; LFM A12; LFM A13

Latest Information Update: 06 Sep 2010

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Paradigm Pharmaceuticals
Class Isoxazoles; Small molecules
Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Caspase stimulants; Protein tyrosine kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

31 Dec 1999 Preclinical trials in Cancer in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com